Patents by Inventor Chang-Duk JUN

Chang-Duk JUN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cancer-treating recombinant protein that improves the activity of cytotoxic killer cells targeting cancer cells and use thereof
    Patent number: 11440941
    Abstract: A cancer killer cell in which a therapeutic recombinant protein or recombinant protein which improves cytotoxic activity of the cancer killer cell is loaded. In addition, a pharmaceutical composition including the recombinant protein or a recombinant protein-loaded cancer killer cell is disclosed. Further, disclosed is a method for preparing a recombinant protein-loaded cancer killer cell.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: September 13, 2022
    Assignee: Gwangju Institute of Science and Technology
    Inventors: Chang-Duk Jun, Bu Nam Jeon, Hey-Ran Kim
  • A CANCER-TREATING RECOMBINANT PROTEIN THAT IMPROVES THE ACTIVITY OF CYTOTOXIC KILLER CELLS TARGETING CANCER CELLS AND USE THEREOF
    Publication number: 20190309036
    Abstract: A cancer killer cell in which a therapeutic recombinant protein or recombinant protein which improves cytotoxic activity of the cancer killer cell is loaded. In addition, a pharmaceutical composition including the recombinant protein or a recombinant protein-loaded cancer killer cell is disclosed. Further, disclosed is a method for preparing a recombinant protein-loaded cancer killer cell.
    Type: Application
    Filed: August 27, 2018
    Publication date: October 10, 2019
    Applicant: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Chang-Duk JUN, Bu Nam JEON, hey-ran KIM
  • Pharmaceutical Compositions for Preventing and Treating Th1 or Th2 mediated Immune Disease Comprising 4H3MC(4-Hydroxy-3-methoxycinnamaldehyde) as an Active Ingredient
    Publication number: 20170252306
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating Th1- or Th2-mediated disease, which comprises 4H3MC (4-hydroxy-3-methoxycinnamaldehyde) as an active ingredient. 4H3MC (4-hydroxy-3-methoxycinnamaldehyde) according to the present invention shows the effect of inhibiting T-cell activity without inducing T-cell death. Thus, 4H3MC (4-hydroxy-3-methoxycinnamaldehyde) according to the present invention can be developed into an effective therapeutic agent against Th1- or Th2-mediated disease, etc.
    Type: Application
    Filed: January 4, 2017
    Publication date: September 7, 2017
    Inventors: Chang-Duk JUN, Uroos Akber, Hyun Su LEE